Advertisement

Management of Angina

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Angina is a pain in the chest or adjacent areas caused by severe, but temporary, lack of blood (ischemia) to a segment of heart muscle, hence the term myocardial ischemia. For stable angina, the most important feature is the causation of pain by a particular exertional activity and relief within minutes of cessation of the precipitating activity.

Keywords

Percutaneous Coronary Intervention Calcium Antagonist Unstable Angina Stable Angina Isosorbide Dinitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cruickshank JM. Beta-blockers continue to surprise us. Eur Heart J 2000;21:354.PubMedCrossRefGoogle Scholar
  2. 2.
    Khan M Gabriel. Angina. In: Heart Disease, Diagnosis and Therapy. owa, NJ, Humana Press 2005.Google Scholar
  3. 3.
    Norwegian MultiCenter Study Group. Timolol-induced reduction in mortality and reinf arction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801.Google Scholar
  4. 4.
    CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with LV dysfunction. Lancet 2001;357:1385.CrossRefGoogle Scholar
  5. 5.
    Pepine CJ, Cohn PF, Deedwania PC, et al. Effect of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study (ASSIST). Circulation 1994; 90:762.PubMedGoogle Scholar
  6. 6.
    Laukkanen JA, Kurl S, Lakka TA, et al. Exercise induced silent myocardial ischemia and coronary morbidity and mortality in middle aged men. J Am Coll Cardiol 2001 38:72.PubMedCrossRefGoogle Scholar
  7. 7.
    Deedwania PC. Silent ischemia predicts poor outcome in high risk healthy men. J Am Coll Cardiol 2001; 38:80.PubMedCrossRefGoogle Scholar
  8. 8.
    Deanfield JE, Selwyn AP, Chierchia S, et al. Myocardial ischaemia during daily life in patients with stable angina: Its relation to symptoms and heart rate changes. Lancet 1983;2:753.PubMedCrossRefGoogle Scholar
  9. 9.
    Deanfield JE, Shea M, Kensett M, etal. Silent myocardial ischemia due to mental stress. Lancet 1984;2: 1001.PubMedCrossRefGoogle Scholar
  10. 10.
    Deanfield JE. Holter monitoring in assessment of angina pectoris. Am J Cardiol 1987;59:18C.PubMedCrossRefGoogle Scholar
  11. 11.
    Cohn PF. Total ischemic burden: Pathophysiology and prognosis. Am J Cardiol 1987;59:3C.PubMedCrossRefGoogle Scholar
  12. 12.
    Pepine CT, Hill JA. Management of the total ischemic burden in angina pectoris. Am J Cardiol 1987; 59:7C.PubMedCrossRefGoogle Scholar
  13. 13.
    Prakash C, Deedwania, Carlsajal EV, et al. Anti-ischemic effects of atenolol and nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963.Google Scholar
  14. 14.
    vonArnim T, for the TIBBS investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995;25:231.CrossRefGoogle Scholar
  15. 15.
    Furberg CD, Friedwald WT, Eberlain KA (eds). Proceedings of the workshop on implications on recent beta-blocker trials for post-myocardial infarction patients. Circulation 1983;67(Suppl III): 1.Google Scholar
  16. 16.
    PRAISE: Packer M, O’Connor CM, Ghoul JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1196;335:1107.CrossRefGoogle Scholar
  17. 17.
    Subramanian B, Bowles MJ, Davies AB, et al. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol 1982;49:125.PubMedCrossRefGoogle Scholar
  18. 18.
    O’Hara MJ, Khurmi NS, Bowles MJ, et al. Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris. Clin Cardiol 1987;10:115.PubMedCrossRefGoogle Scholar
  19. 19.
    Elkayam U. Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance and strategies for prevention. Ann Intern Med 1991;114:667.PubMedGoogle Scholar
  20. 20.
    Packer M, Le WH, Kessler P, et al. Induction of nitrate tolerance in heart failure by continuous infusion of nitroglycerin and reversal of tolerance by N-acetylcysteine, a sulfhydryl donor (abstract). J Am Coll Cardiol 1986;7:27A.Google Scholar
  21. 21.
    Abrams J. Interval therapy to avoid nitrate tolerance: Paradise regained. Am J Cardiol 198964:931.Google Scholar
  22. 22.
    Rudolph W. Tolerance development during isosorbide dinitrate treatment: Can it be circumvented? Z Kardiol 1983;72:195.PubMedGoogle Scholar
  23. 23.
    Sharpe N, Coxon R, Webster M, et al. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987;59:895.PubMedCrossRefGoogle Scholar
  24. 24.
    Juul Moller S, Edvardsson N, Jhnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. Lancet 1992;340:1421.CrossRefGoogle Scholar
  25. 25.
    Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet 2001;358:1533.PubMedCrossRefGoogle Scholar
  26. 26.
    Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986;314:1214.PubMedCrossRefGoogle Scholar
  27. 27.
    Nademanee K, Intarachot V, Josephson MA, et al. Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol 1987;10:1.PubMedGoogle Scholar
  28. 28.
    Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396.PubMedCrossRefGoogle Scholar
  29. 29.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 1985; 313:1369.PubMedCrossRefGoogle Scholar
  30. 30.
    Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in the intermediate coronary syndrome. Lancet 1981;1:1225.PubMedCrossRefGoogle Scholar
  31. 31.
    RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827.CrossRefGoogle Scholar
  32. 32.
    Theroux P, Ouimet H, McCans J. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988; 319:1105.PubMedCrossRefGoogle Scholar
  33. 33.
    Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Cardiol 1994;24:39.CrossRefGoogle Scholar
  34. 34.
    Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045.PubMedGoogle Scholar
  35. 35.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.PubMedCrossRefGoogle Scholar
  36. 36.
    Platelet Receptor Inhibitor Ischemic Syndrome Management (PRISM) study investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498.CrossRefGoogle Scholar
  37. 37.
    PRISM-PLUS: Platelet Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998;338:1488.CrossRefGoogle Scholar
  38. 38.
    Muhlestin JB, Hammond EH, Carlsquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555.CrossRefGoogle Scholar
  39. 39.
    Gurfinkel E, Bozavich G, Daroca A, et al. for the ROXIS Study Group. Randomized trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404.PubMedCrossRefGoogle Scholar
  40. 40.
    Cannon CP, Braunwald E, McCabe CH, et al. for thePravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646–1654.PubMedCrossRefGoogle Scholar
  41. 41.
    Khan M Gabriel. Atherosclerosis. In: Encyclopedia of Heart Diseases. San Diego, Academic Press, 2006, p. 121.Google Scholar
  42. 42.
    Feldman RL. A review of medical therapy for coronary artery spasm. Circulation 1987;75(Suppl V):V–96.Google Scholar
  43. 43.
    Miwa K. Kambara H, Kawai C. Effect of aspirin in large doses on attacks of variant angina. Am Heart J 1983;105:351.PubMedCrossRefGoogle Scholar
  44. 44.
    Pitt B, Waters D, Brown WV, et al. for the Atorvastatin Versus Revascularization Treatment investigators. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70–76.PubMedCrossRefGoogle Scholar
  45. 45.
    HOPE Investigators. Yusuf S, Sleigh P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. The Heart Outcomes Prevention Evaluation Investigators. N Engl J Med 2000;342:145–153.PubMedCrossRefGoogle Scholar
  46. 46.
    RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: The second Randomized Intervention Treatment of Angina (RITA-2 Trial). Lancet 1997;350:461–468.CrossRefGoogle Scholar
  47. 47.
    ARTS: Serruys PW, Unger F, Sousa JE, et al. for the Arterial Revascularization Therapies study group. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;1344:1117–1124.CrossRefGoogle Scholar
  48. 48.
    Niles NW, McGrath PD, Malenka D, et al. for the northern New England Cardiovascular Disease Study group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revaacularization: Results of a large regional prospective study. J Am Coll Cardiol 2001; 37:1008–1015.PubMedCrossRefGoogle Scholar
  49. 49.
    BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122–1129.CrossRefGoogle Scholar
  50. 50.
    King SB. Coronary artery bypass graft or percutaneous coronary interventions in patients with diabetes: another nail in the coffin or “too close to call”? J Am Coll Cardiol 2001;37:1016–1018.PubMedCrossRefGoogle Scholar
  51. 51.
    TACTICS: Cannon CP, Weintraub WS, Demopoulos LA, et al. for the Thrombolysis in Myocardial Infarction 18 investigators. Comparison of early and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein llb/lla inhibitor tirofiban. N Engl J Med 2001;344: 1879–1887.PubMedCrossRefGoogle Scholar
  52. 52.
    CURE: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.CrossRefGoogle Scholar
  53. 53.
    PCI/CURE: Mehta SR, Yusuf S, Peters RJ, et al. for the clopidogrel in unstable angina to prevent recurrent events trial. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy inpatients undergoing percutaneous coronary intervention. Lancet 2001 358:527–533.PubMedCrossRefGoogle Scholar
  54. 54.
    CHARISMA: Bhatt DL, Fox KAA, Hacke W, for the CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Cairns JA. Ranolazine: Augmenting the antianginal armamentarium. J Am Coll Cardiol 2006;48:576–578.PubMedCrossRefGoogle Scholar
  2. Jespersen.
    CM, Als-Nielsen B, Damgaard M, et al. CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22–27.CrossRefGoogle Scholar
  3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1–121.PubMedCrossRefGoogle Scholar
  4. Stone.
    PH, Gratsiansky NA, Blokhin A, for the ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–575.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations